GCS-β-1 Antibody (G-3): sc-514183

GCS-β-1 Antibody (G-3) is a mouse monoclonal IgG1 kappa light chain antibody that detects GCS-beta-1 of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). GCS-β-1 (G-3) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. GCS-beta-1, also known as soluble guanylate cyclase (sGC), plays a pivotal role in cellular signaling as the primary receptor for nitric oxide (NO). GCS-beta-1 is crucial for cyclic guanosine monophosphate (cGMP) synthesis, a secondary messenger regulating various physiological processes, including smooth muscle relaxation, neurotransmission, and platelet aggregation. GCS is a heme-containing heterodimer composed of an alpha and beta subunit, with the heme moiety being essential for NO activation. GCS can also bind carbon monoxide, providing weaker enzyme stimulation. NO and carbon monoxide activation can be further enhanced by the allosteric activator YC-1, which can stimulate GCS independently of NO. Both subunits are necessary for effective cGMP generation, and multiple isoforms exist for each subunit, with heterodimers such as α-1/β-1 and α-2/β-1 exhibiting similar enzymatic activity. β-2 subunit expression is notably more restricted compared to β-1 subunit, with significant expression found in the kidney and liver, highlighting GCS importance in various organ systems and potential implications in vascular and neurological health.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

GCS-β-1 Antibody (G-3) References:

1. Rapid desensitization of the nitric oxide receptor, soluble guanylyl cyclase, underlies diversity of cellular cGMP responses.  |  Bellamy, TC., et al. 2000. Proc Natl Acad Sci U S A. 97: 2928-33. PMID: 10717006
2. Human recombinant soluble guanylyl cyclase: expression, purification, and regulation.  |  Lee, YC., et al. 2000. Proc Natl Acad Sci U S A. 97: 10763-8. PMID: 10995472
3. Subunits of the nitric oxide receptor, soluble guanylyl cyclase, expressed in rat brain.  |  Gibb, BJ. and Garthwaite, J. 2001. Eur J Neurosci. 13: 539-44. PMID: 11168561
4. Nitric oxide activates the beta 2 subunit of soluble guanylyl cyclase in the absence of a second subunit.  |  Koglin, M., et al. 2001. J Biol Chem. 276: 30737-43. PMID: 11406623
5. Regional and age-dependent expression of the nitric oxide receptor, soluble guanylyl cyclase, in the human brain.  |  Ibarra, C., et al. 2001. Brain Res. 907: 54-60. PMID: 11430885
6. YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components.  |  Martin, E., et al. 2001. Proc Natl Acad Sci U S A. 98: 12938-42. PMID: 11687640
7. A new form of guanylyl cyclase is preferentially expressed in rat kidney.  |  Yuen, PS., et al. 1990. Biochemistry. 29: 10872-8. PMID: 1980215
8. Therapeutic Targeting of the Soluble Guanylate Cyclase.  |  Makrynitsa, GI., et al. 2019. Curr Med Chem. 26: 2730-2747. PMID: 30621555
9. Soluble Guanylate Cyclase Stimulators in Heart Failure.  |  Kansakar, S., et al. 2021. Cureus. 13: e17781. PMID: 34659992
10. Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum.  |  Butler, J., et al. 2022. Eur J Heart Fail. 24: 2029-2036. PMID: 36250238
11. Pericyte signaling via soluble guanylate cyclase shapes the vascular niche and microenvironment of tumors.  |  Zhu, J., et al. 2024. EMBO J. 43: 1519-1544. PMID: 38528180
12. Functional domains of soluble guanylyl cyclase.  |  Wedel, B., et al. 1995. J Biol Chem. 270: 24871-5. PMID: 7559610

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-GCS-β-1 Antibody (G-3) has 4 citations in a variety of scientific publications.

Primary antibodies like Anti-GCS-β-1 Antibody (G-3) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

GCS-β-1 Antibody (G-3) Specifications

Alternate Product Name: GCS-β-1

Product Clone Name: G-3

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 541-619

Epitope Target: GCS-β-1

Epitope Species: human

Product Reactivity/Detection: GCS-β-1

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 4 citations in various scientific publications

Available Conjugates/Forms for GCS-β-1 Antibody (G-3): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin